News

15 May

Clinical Trial Integrity and COVID-19

19 January

Statement to EB148 on the COVID-19 response

14 October

FACT SHEET: Impact and Knowledge of COVID-19 and related measures in rural Kenyan households

4 June

COVID-19 Technology Access Pool

26 May

Letter to Dr Tedros: The Challenge of Access to Insulin Amidst COVID-19

25 March

The fight against COVID-19: let’s make public investments count for people

1 August

Response to European Consultation on Intellectual Property

7 June

IP in a Post-pandemic World

24 April

Annual Report 2022

24 January

Diagnostics to Address Antimicrobial Resistance

21 November

Licensing and Access to Health Technologies

19 October

The TRIPS Agreement Laid Bare

15 June

HAI Statement to Intergovernmental Negotiating Body

25 May

Statement to WHA75 – Health Emergencies

2 May

Response to European Consultation on Compulsory Licensing

24 November

Medicine Pricing and Access in Europe

21 September

Eudamed and CTIS: Lessons from EudraCT

15 September

Transparency and Medicines Policy in the EU

29 May

Statement to WHA74 on GSPOA

3 May

HAI Statement on The Oslo Medicines Initiative at the WHO Virtual Consultation with Non-State Actors, 31 March 2021

1 March

Response to EU’s HERA Initiative Consultation

10 February

Transparency, Accountability and Access to Medicines: European Projects 2021

22 January

Statement to EB148 on WHO reform: involvement of non-State actors in WHO’s governing bodies

21 January

Letter to Dr Tedros: Leadership and Advocacy for C-TAP

18 January

Statement to EB148 on global strategy and plan of action on public health, innovation and intellectual property

18 December

Joint HTA Assessment in Europe: Progress in 2020

14 December

Cross-country Cooperation Schemes: A fair-weather solution to the issue of access to medicines in Europe?

31 July

European Commission Intellectual Property Action Plan

11 June

Driving Change in Access to Medicines – Annual Report 2019